Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges

Vaccine

Volumn 27, Issue 46, 2009, Pages 6468-6470

  Frasch, Carl E ^a  

^a Frasch Biologics Consulting   (United States)

Author keywords

Conjugate; Manufacture; Vaccine

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PERIODATE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PROTEIN;

ARTICLE; CONJUGATION; FERMENTATION; HYDROLYSIS; IMMUNOGENICITY; MOLECULAR SIZE; OXIDATION; PRIORITY JOURNAL; PURIFICATION; QUALITY CONTROL; T LYMPHOCYTE; VACCINE PRODUCTION;

BACTERIAL PROTEINS; POLYSACCHARIDES, BACTERIAL; QUALITY CONTROL; TECHNOLOGY, PHARMACEUTICAL; VACCINES, CONJUGATE;

EID: 70350070727     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.013     Document Type: Article

References (23)

1. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19 3 (2000) 187-195
2. Lucas A.H., Apicella M.A., and Taylor C.E. Carbohydrate moieties as vaccine candidates. Clin Infect Dis 41 5 (2005) 705-712
3. Frasch C.E. Regulatory perspectives in vaccine licensure. In: Ellis R.W., and Granoff D.M. (Eds). Development and clinical uses of Haemophilus b conjugate vaccines (1994), Marcel Dekker, New York 435-453
4. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl. 1 (2001) S58-S67
5. Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 70 1 (2004) 1-14
6. WHO technical report series, No. 897. Annex 1 Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines; 2000.
7. WHO technical report series, No. 924. Annex 2 Recommendations for the production and control of meningococcal group C conjugate vaccines; 2004.
8. WHO technical report series, No. 927. Annex 2 Recommendations for the production and control of pneumococcal conjugate vaccines; 2005.
9. Foresgren A., Riesbeck K., and Janson H. Protein D of Haemophilus influenzae: a protective nontypable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 46 (2008) 726-731
10. Anderson P.W., Pichichero M.E., Stein E.C., Porcelli S., Betts R.F., Connuck D.M., et al. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM197. J Immunol 142 (1989) 2464-2468
11. Kniskern P.J., and Marburg S. Conjugation: design, chemistry, and analysis. In: Ellis R.W., and Granoff D.M. (Eds). Development and clinical uses of Haemophilus b conjugate vaccines (1994), Marcel Dekker, New York 37-69
12. Lees A., Nelson B.L., and Mond J.J. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14 (1996) 190-198
13. Bhushan R., Anthony B.F., and Frasch C.E. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent. Infect Immun 66 12 (1998) 5848-5853
14. Schneerson R., Barrera O., Sutton A., and Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J Exp Med 152 (1980) 361-376
15. Chu C., Schneerson R., Robbins J.B., and Rastogi S.C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6B polysaccharide-protein conjugates. Infect Immun 40 (1983) 245-256
16. Lee C.-H., Kuo W.C., Beri S., Kapre S., Joshi J.S., Bouveret N., et al. Preparation and characterization of a highly immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 27 5 (2009) 726-732
17. Lees A., Sen G., and Loppez-Acosta A. Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine 24 6 (2006) 716-729
18. Xu Q.W., Klees J., Teyral J., Capen R., Huang M., Sturgess A.W., et al. Quantitative nuclear magnetic resonance analysis and characterization of the derivatized Haemophilus influenzae type b polysaccharide intermediate for PedvaxHIB. Anal Biochem 337 2 (2005) 235-245
19. Jones C. NMR assays for carbohydrate-based vaccines. J Pharm Biomed Anal 38 5 (2005) 840-850
20. Talaga P., Vialle S., and Moreau M. Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates. Vaccine 20 19-20 (2002) 2474-2484
21. Tsai C.-M., Gu X.-X., and Byrd R.A. Quantification of polysaccharide in Haemophilus influenzae type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection. Vaccine 12 (1994) 700-706
22. Xu Q.W., Abeygunawardana C., Ng A.S., Sturgess A.W., Harmon B.J., and Hennessey J.P. Characterization and quantification of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharide preparations. Anal Biochem 336 2 (2005) 262-272
23. Trotter C.L., McVernon J., Ramsay M.E., Whitney C.G., Mulholland K., Goldblatt D., et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26 35 (2008) 4434-4445